# A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

> **NCT06732154** · PHASE1 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** HRS-5632
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06732154
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-02
- **Primary completion:** 2026-03-02
- **Final completion:** 2026-03-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732154, "A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06732154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*